Maritide (CT-388): Roche New Weight Loss Drug Explained

Maritide (CT-388): Roche New Weight Loss Drug Explained

The conversation around weight management is evolving rapidly, with new medications offering promising avenues for health. You may have heard about GLP-1 drugs, and now, a new generation of treatments is emerging. One of the latest developments in this field is an investigational drug called maritide, also known as CT-388, from the pharmaceutical company Roche.

This article provides a clear, evidence-aware guide to what maritide is, how it works, and what the early research suggests. As with any health topic, knowledge is key to understanding your options and having informed conversations. Consult your healthcare provider before starting any medication.

What is Maritide (CT-388)?

Maritide is an investigational medication being studied for the treatment of obesity and type 2 diabetes. "Investigational" is a key term here—it means the drug has not yet been approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is still undergoing clinical trials to determine its safety and effectiveness.

The drug was originally developed by a company called Carmot Therapeutics, which was acquired by Roche in late 2023. This acquisition placed maritide into the pipeline of one of the world's largest pharmaceutical companies, signaling significant interest in its potential.

Maritide belongs to a class of drugs known as dual agonists, which means it is designed to act on two different hormone receptors in the body to influence appetite, food intake, and metabolism.

How Does Maritide Work? The Science of Dual Agonists

To understand maritide, we first need to look at two important hormones produced naturally in our gut: GLP-1 and GIP. These hormones are released after we eat and play a crucial role in managing blood sugar and appetite. Maritide is designed to mimic the actions of both.

Understanding GLP-1

GLP-1 (glucagon-like peptide-1) is a hormone that has several important functions:

• It stimulates insulin release: When blood sugar levels rise after a meal, GLP-1 helps the pancreas release the right amount of insulin.
• It slows digestion: It slows down the rate at which food leaves the stomach, helping you feel fuller for a longer period.
• It signals the brain: GLP-1 acts on appetite centers in the brain, reducing hunger signals and cravings.

Many existing weight management medications, such as semaglutide (found in Ozempic and Wegovy) and liraglutide (found in Saxenda), are GLP-1 receptor agonists. They work by activating this single pathway.

The Role of GIP

GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone that, like GLP-1, helps with insulin release. For a long time, its role in weight management was less clear. However, recent research suggests that GIP may also play a part in how the body processes calories and stores fat. Some studies indicate it may enhance the weight loss effects of GLP-1 and improve metabolic health.

The Power of Two

Maritide is a dual GLP-1/GIP receptor agonist. This means it is engineered to activate both the GLP-1 and GIP receptors simultaneously. The scientific thinking behind this approach is that engaging two distinct hormonal pathways could lead to a more powerful effect on weight loss and blood sugar control than targeting GLP-1 alone.

This dual-action mechanism is not entirely new. The medication tirzepatide (found in Mounjaro and Zepbound) is also a dual GLP-1/GIP agonist. Maritide represents another potential option within this promising class of treatments.

What the Early Research Shows

It's important to remember that maritide is still in the early stages of research. The most significant public information comes from a small Phase 1b clinical trial, the results of which were shared by Roche in early 2024.

In this study, which involved a small number of participants with obesity, those who received a weekly injection of maritide for 24 weeks saw significant weight loss. Roche reported an average weight loss of nearly 19% in the group receiving the highest dose of the drug. This was compared to a small amount of weight loss in the group that received a placebo (an injection with no active medicine).

The side effects reported in the trial were generally consistent with other medications in this class. These typically include gastrointestinal issues like nausea, vomiting, and diarrhea, which are often most pronounced when starting the medication or increasing the dose.

While these results are notable, they come from a very early and small study. Much larger and longer-term studies, known as Phase 2 and Phase 3 trials, are required to confirm these findings, fully understand the drug's safety profile, and determine its long-term effects.

What Happens Next for Maritide?

Maritide is now advancing to Phase 2 clinical trials. This is a critical step in the drug development process where researchers will:

• Test different doses to find the optimal balance between effectiveness and side effects.
• Evaluate the drug's safety in a larger and more diverse group of people.
• Gather more data on how well it works for weight management and, in separate trials, for type 2 diabetes.

This process is meticulous and takes time. Even if Phase 2 and subsequent Phase 3 trials are successful, it will likely be several years before maritide could become available as a prescribed medication.

A Practical Perspective on New Medications

The development of drugs like maritide is part of a major shift in how the medical community understands and approaches the biology of weight. It reinforces that weight is regulated by complex hormonal signals, not just willpower.

As new treatments emerge, it is an opportunity to have more productive conversations with healthcare professionals about what a comprehensive and personalized approach to weight health looks like. For many, this includes a combination of lifestyle changes—such as nutrition, physical activity, and behavioral support—along with medical treatments when appropriate. Staying informed through trusted sources is a great step in your health journey.

The path to a healthier life is unique for every individual. Consult your healthcare provider before starting any medication.

Sources

• https://www.roche.com/media/releases/med-cor-2024-02-05
• https://www.clinicaltrials.gov/study/NCT05518464
• https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
• https://www.fiercebiotech.com/biotech/roche-posts-phase-1-obesity-data-carmot-buyout-drug-takes-19-weight
• https://www.reuters.com/business/healthcare-pharmaceuticals/roche-reports-promising-data-new-obesity-drug-candidate-2024-02-05/